Press Releases

October 31, 2008

Bilcare Consolidated Sales for the quarter ended September 30, 2008 up at Rs 211.04 Cr; Net Profit at Rs 14.62 Cr.

Click here to download PDF

Pune, October 31, 2008: Bilcare Ltd., service provider to the pharmaceutical companies spanning across their value chain from drug discovery to market, posted their results for the second quarter ended September 30th, 2008.

For the second quarter ended September 30, 2008, the India stand alone sales of the Company stood at Rs 118.61 Cr. as against Rs 97.95 Cr. in the corresponding quarter of the previous year, showing a growth of 21 percent. This resulted in a better operating EBITDA of Rs 31.33 Cr. as against Rs 26.70 Cr. in the corresponding quarter of the previous year, registering a growth of 17 percent. Net profit was at Rs 11.31 Cr.

For the half year ended September 30, 2008, the India stand alone sales were higher by 22% at Rs 232.37 Cr. as compared to Rs 190.83 Cr. in the corresponding period of the previous year.

The Consolidated Sales for the second quarter of FY09 stood at Rs 211.04 Cr. with an EBIDTA of Rs 30.14 Cr. and Net Profit of Rs 14.62 Cr.

The Consolidated sales for the first half were higher by 48% at Rs 398.54 Cr. as compared to the corresponding period in the previous year. This resulted in the EBIDTA levels being higher by 25% at Rs 84.86 Cr. as compared to Rs 68.06 Cr. in the corresponding period of the previous year. Net Profit stood at Rs 35.70 Cr.

"During this quarter, the overseas sales growth has been more than 130% as a resultant of the investments made earlier.

With India sales growth at 21%, the overall business grew by 50%." said, Mohan Bhandari, Chairman & Managing Director, Bilcare Limited.

About Bilcare Research:

Bilcare (BSE code526853) is an international, integrated service provider to the global pharmaceutical industry offering one stop solution in pharma packaging research, global clinical trial supplies services, brand protection & authentication technology and an acclaimed research academy. Bilcare operates state-of-the-art manufacturing and research facilities in India, Singapore, USA, UK and has regional offices in Brazil, Germany, China and Australia. Bilcare is committed to the pharmaceutical industry's key concerns viz. Counterfeit, Compliance, Costs, Communication and Convenience.